+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial



Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial



Drug Intelligence and Clinical Pharmacy 17(1): 51-54



Oxprenolol (OX) is a nonselective, beta-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p less than 0.001) and pulse 8 beats/min in the SR-OX group (n = 67) and 24/17 mm Hg (p less than 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 044341895

Download citation: RISBibTeXText

PMID: 6337801

DOI: 10.1177/106002808301700115


Related references

Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation. British Journal of Clinical Pharmacology 12(6): 869-871, 1981

Comparison of a slow-release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension. Clinical Science and Molecular Medicine. Supplement 3: 559s-561s, 1976

A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension. European Journal of Clinical Pharmacology 14(2): 77-82, 1978

Comparison of the activity and plasma levels of oxprenolol slow release oxprenolol long acting propranolol and sotalol. European Journal of Clinical Pharmacology 17(6): 419-424, 1980

Oxprenolol slow-release with cyclopenthiazide-KCl compared with methyldopa in the treatment of essential hypertension. A multicentre general practice trial. South African Medical Journal 54(21): 860-864, 1978

Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily. American Journal of Cardiology 47(5): 1123-1127, 1981

Effect of slow oxprenolol and a combination of slow oxprenolol and cyclopenthiazide on plasma lipoproteins. Atherosclerosis 39(3): 301-306, 1981

Reduction of left ventricular hypertrophy and increased tolerance to exertion in hypertensive patients after antihypertensive therapy with slow-release oxprenolol and chlorthalidone. Cardiologia 31(9): 701-708, 1986

Effects of chronic administration of the fixed combination slow-release oxprenolol-chlorthalidone on left ventricular hypertrophy in hypertensive patients. Echocardiographic study. International Journal of Clinical Pharmacology, Therapy, and Toxicology 26(3): 148-152, 1988

A comparison of slow Trasicor (oxprenolol 160 mg) and Trasidrex (oxprenolol 160 mg and cyclopenthiazide 0.25 mg) in the treatment of hypertension in general practice. Journal of International Medical Research 9(5): 315-318, 1981

Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris. Journal of International Medical Research 7(3): 194-200, 1979

A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects. British Journal of Clinical Pharmacology 3(3): 439-443, 1976

Controlled clinical trial between methyl dopa and oxprenolol in hypertensive nigerians. Federation Proceedings 36(3): 1049, 1977

Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects. British Journal of Clinical Pharmacology 21(4): 371-376, 1986

Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris. European Journal of Clinical Pharmacology 32(2): 127-134, 1987